IGF2BP3 binds to FBXO32 to activate the cyclic guanosine monophosphate-protein kinase G pathway, promoting gastric cancer progression

Figure 7 Oncogenic function of IGF2BP3 depends on FBXO32 and cyclic guanosine monophosphate-protein kinase G signaling pathway. A: Expression of IGF2BP3 messenger RNA in HGC-27 cells as measured by quantitative reverse transcription polymerase chain reaction after co-transfection of small interfering RNA (siRNA)-negative control (siNC) or siRNA-IGF2BP3 (siIGF2BP3), and pcDNA3.1 (vector) or pcDNA3.1-FBXO32 (FBXO32) plasmids; B: Kyoto Encyclopedia of Genes and Genomes enrichment results for the top 1000 genes co-expressed with FBXO32 in gastric adenocarcinoma in the Cancer Genome Atlas; C: Expression levels of proteins related to the cyclic guanosine monophosphate-protein kinase G signaling pathway as detected by western blot after instantaneous co-transfection of siNC/siIGF2BP3 and vector/FBXO32 in HGC-27 cells; D-H: Effects of FBXO32 on IGF2BP3 in HGC-27 cells as detected by cell counting kit-8 (CCK-8) assay (D), colony formation assay (E), and wound healing assay (F) (scale bar: 200 μm), transwell migration assay (G), and transwell invasion assay (H) (scale bar: 100 μm); I: Half-maximal inhibitory concentration of KT5823 as determined in HGC-27 cells using CCK-8 assay; J: Measurement of HGC-27 cell proliferation by CCK-8 assay following different treatments; K: Measurement of HGC-27 cell proliferation by colony formation assay following different treatments. Data are presented as the mean ± SD. ^aP < 0.05. ^bP < 0.01. ^cP < 0.001. ^dP < 0.0001. mRNA: Messenger RNA; GAPDH: Glyceraldehyde-3-phosphate dehydrogenase; siNC: Small interfering RNA-negative control; siIGF2BP3: Small interfering RNA-IGF2BP3; cGMP: Cyclic guanosine monophosphate; PKG: Protein kinase G; p-VASP: Phospho-VASP; OD: Optical density; IC₅₀: The half maximal inhibitory concentration.